First Allied Advisory Services Inc. lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,854 shares of the biopharmaceutical company’s stock after purchasing an additional 226 shares during the quarter. First Allied Advisory Services Inc.’s holdings in Regeneron Pharmaceuticals were worth $827,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Fieldpoint Private Securities LLC bought a new position in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $130,000. Sterling Investment Advisors Ltd. increased its holdings in shares of Regeneron Pharmaceuticals by 11.2% during the second quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 28 shares during the period. FNY Partners Fund LP increased its holdings in shares of Regeneron Pharmaceuticals by 200.0% during the second quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 200 shares during the period. IFP Advisors Inc increased its holdings in shares of Regeneron Pharmaceuticals by 33.2% during the second quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 96 shares during the period. Finally, Virtu KCG Holdings LLC bought a new position in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $206,000. 66.67% of the stock is currently owned by institutional investors.

Several research analysts have recently commented on REGN shares. Leerink Swann reaffirmed a “positive” rating and set a $552.00 target price (down from $580.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 15th. BMO Capital Markets set a $444.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a report on Monday, November 27th. Citigroup cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $480.00 to $380.00 in a report on Friday, December 1st. Robert W. Baird raised shares of Regeneron Pharmaceuticals from an “underperform” rating to a “neutral” rating in a report on Friday, November 3rd. Finally, Zacks Investment Research cut shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Two analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. Regeneron Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $467.84.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at $381.32 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $340.09 and a 52-week high of $543.55. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.07. The firm has a market cap of $40,910.63, a P/E ratio of 32.97, a price-to-earnings-growth ratio of 1.50 and a beta of 1.53.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, beating analysts’ consensus estimates of $3.83 by $0.16. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The firm had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.45 billion. During the same quarter last year, the business posted $3.13 earnings per share. The company’s quarterly revenue was up 23.0% on a year-over-year basis. equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 13.55 EPS for the current fiscal year.

In other news, Director Michael S. Brown sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $475.00, for a total transaction of $712,500.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Charles A. Baker sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, September 29th. The stock was sold at an average price of $450.00, for a total transaction of $900,000.00. Following the transaction, the director now owns 11,000 shares in the company, valued at approximately $4,950,000. The disclosure for this sale can be found here. 10.80% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: This piece was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/regeneron-pharmaceuticals-inc-regn-shares-bought-by-first-allied-advisory-services-inc/1759134.html.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.